Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program

• Published in: Journal of geriatric oncology Vol. 11; no. 5; pp. 796 - 801
• Main Authors: Joris, Sofie, Pieters, Thierry, Sibille, Anne, Bustin, Fréderique, Jacqmin, Laurence, Kalantari, Hassan Rezaei, Surmont, Veerle, Goeminne, Jean-Charles, Clinckart, Frederic, Pat, Karin, Demey, Wim, Deschepper, Koen, Lambrechts, Marc, Holbrechts, Stephane, Schallier, Denis, Decoster, Lore
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01-06-2020
• Subjects: Nivolumab; Non-small cell lung cancer; Older; Performance status; Nivolumab; Performance status; Non-small cell lung cancer; Older
• ISSN: 1879-4068; 1879-4076
• DOI: 10.1016/j.jgo.2019.09.011

To compare real life effectiveness and safety of nivolumab in patients with non-small cell lung cancer (NSCLC), according to age and Eastern Cooperative Group performance status (ECOG-PS).
We performed a retrospective analysis of patients treated with nivolumab for NSCLC within a Belgian compassionate use program from July 2015 until December 2016. Safety and effectiveness were compared between patients aged ≥70 years and < 70 years and between ECOG-PS 0/1 and ≥ 2.
A total of 324 patients with NSCLC were included. There was no significant difference between older (≥70) and younger (<70 years) patients with regards to progression free survival (PFS) (4 months (95%CI 2.6;4.8) versus 3.7 months (95%CI 1;7), p = 0.483) and overall survival (OS) (9.3 months (95% CI 5.5;13.1 months) versus 8.4 months (95%CI 6.3; 10.5), p = 0,638). Patients with an ECOG-PS ≥2 had a significant lower median PFS and OS compared to patients with an ECOG-PS 0–1 (2.2 (95%CI 1.4; 2.9) versus 5.6 months (95%CI 4.1; 7.1), p = 0.001 and 3.4 (95%CI 2.3; 4.5) versus 11.1 months (95%CI 8.9; 13.2), p < 0.001 respectively).
No significant difference in all grades or grade 3/4 adverse events (AEs) were observed between the different age groups (p = 0.526 and p = 0.603 respectively). Patients with an ECOG-PS 0/1 had significantly more all grades AEs (p = 0.009) but no difference in grade 3/4 AEs was observed (p = 0.406) compared to ECOG-PS ≥2.
This real life retrospective study confirms that safety and effectiveness of nivolumab is similar between different age groups, but that effectiveness is driven by performance status.